Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 20/20 | 0.84 |
| ▸ | EDNRB | P24530 | 14/20 | 0.84 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.84 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.84 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.84 |
| ▸ | DHPS | P49366 | 1/20 | 0.84 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.84 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7795452 | 0.95 | EDNRA (0.93) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7787008 | 0.92 | EDNRA (0.86) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL5682394 | 0.92 | EDNRA (0.87) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL29485039 | 0.92 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL3981779 | 0.92 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL902870 | 0.92 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL4218 | 0.92 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL5493152 | 0.92 | EDNRA (0.84) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL628837 | 0.91 | EDNRA (0.98) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL15257223 | 0.91 | EDNRA (0.86) | EDNRAEDNRBABCC3ABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139537-B2 | Process for preparation of bosentan | MEGAFINE PHARMA(P) LTD. (IN) | 2015-09-22 | — | — | US | disclosed |
| US-20130296560-A1 | Novel Process For Preparation Of Bosentan | MEGAFINE PHARMA (P) LTD. (IN) | 2013-11-07 | — | — | US | disclosed |
| WO-2012056468-A1 | A PROCESS FOR THE PREPARATION OF BOSENTAN | MATRIX LABORATORIES LTD (IN) | 2012-05-03 | — | — | WO | disclosed |
| US-20110021547-A1 | Substantially Pure and a Stable Crystalline Form of Bosentan | ACTAVIS GROUP PTC EHF (IS) | 2011-01-27 | — | — | US | disclosed |
| US-20110014291-A1 | Novel Polymorphs of Bosentan | ACTAVIS GROUP PTC EHF (IS) | 2011-01-20 | — | — | US | disclosed |
| EP-2268634-A2 | PROCESSES FOR THE PREPARATION OF BOSENTAN AND RELATED COMPOUNDS USING NOVEL INTERMEDIATES | Actavis Group PTC EHF (IS) | 2011-01-05 | — | — | EP | disclosed |
| EP-2240469-A2 | SUBSTANTIALLY PURE AND A STABLE CRYSTALLINE FORM OF BOSENTAN | Actavis Group PTC EHF (IS) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009112954-A2 | PROCESSES FOR THE PREPARATION OF BOSENTAN AND RELATED COMPOUNDS USING NOVEL INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009093127-A2 | SUBSTANTIALLY PURE AND A STABLE CRYSTALLINE FORM OF BOSENTAN | ACTAVIS GROUP PTC EHF (IS) | 2009-07-30 | — | — | WO | disclosed |
| EP-1254121-B1 | PREPARATION OF SULFONAMIDES | HOFFMANN LA ROCHE (CH) | 2006-02-01 | — | — | EP | disclosed |
| EP-1254121-A1 | PREPARATION OF SULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055120-A1 | PREPARATION OF SULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-02 | — | — | WO | disclosed |
| US-6136971-A | Preparation of sulfonamides | ROCHE COLORADO CORPORATION (US) | 2000-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014291-A1 | Novel Polymorphs of Bosentan | VASP, EDNRB, ADRA1B | EDNRA 14/4885EDNRB 2/4885ABCC3 835/4885 |
| US-20110021547-A1 | Substantially Pure and a Stable Crystalline Form of Bosentan | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCLN, F5 | EDNRA 29/4885EDNRB 8/4885ABCC3 2066/4885 |
| US-20130296560-A1 | Novel Process For Preparation Of Bosentan | BMP6, EDNRB, PAH | EDNRA 9/4885EDNRB 2/4885ABCC3 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.